Novo Nordisk establishes type 1 diabetes R&D center in Seattle
- Details
- Category: Novo Nordisk
Novo Nordisk will establish a type 1 diabetes R&D center in Seattle, US. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.
Roche supports cancer care development program in Ethiopia
- Details
- Category: Roche
Roche announced a grant to the Albert Einstein College of Medicine of Yeshiva University in New York City, which will be used for the establishment of a program to improve basic cancer care in Ethiopia. The grant funding comes from the Roche African Research Foundation.
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
- Details
- Category: Genzyme
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world's leading biotechnology companies, and Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced a global co-promotion partnership to provide a comprehensive solution for thyroid patients.
Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced a donation of $6.9 million in 2011 to support the HealthWell Foundation, an independent non-profit organization that provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments.
Novartis receives approval for Lucentis® and launches Galvus® in China
- Details
- Category: Novartis
Novartis received regulatory approval in China from the State Food and Drug Administration (SFDA) for Lucentis® (ranibizumab) to treat wet (neovascular) age-related macular degeneration (AMD), and is launching Galvus® (vildagliptin), an oral treatment for patients with type 2 diabetes approved in China as an add-on to metformin,
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
- Details
- Category: Nycomed
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced today strategic measures to better align its global workforce and consolidate site operations in order to integrate legacy Nycomed operations,
Sanofi and Venture Capital Firms, Third Rock Ventures and Greylock Partners launched Warp Drive Bio
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) is co-investing in Warp Drive Bio, an innovative start-up biotechnology company, along with 2 venture capital firms, Third Rock Ventures (TRV), a venture capital firm based in Boston, Massachusetts, and Greylock Partners, a venture capital firm based in Menlo Park, California.
More Pharma News ...
- Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon
- Novartis to restructure US business to strengthen competitive position
- AstraZeneca and IMS Health announce real-world evidence collaboration in Europe
- A New Resource That Offers Personalized Nutritional Guidance to Achieve Better Health
- Bayer HealthCare to Share Lab Space with Start-Up Companies
- AstraZeneca reaffirms December 2011 financial guidance for 2011
- Bristol-Myers Squibb to Acquire Inhibitex